E76.0 Mucopolysaccharidosis, type I

Name of the Condition

• Mucopolysaccharidosis, type I (ICD-10 Code: E76.0)

Summary

Mucopolysaccharidosis, type I (MPS I) is a rare inherited disorder caused by a deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of glycosaminoglycans (GAGs) in tissues. This buildup disrupts normal cellular function, resulting in progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early diagnosis and intervention are critical to manage symptoms and slow disease progression.

Causes

MPS I is caused by genetic mutations in the IDUA gene, which encodes the alpha-L-iduronidase enzyme. These mutations impair the enzyme's ability to break down GAGs, leading to their accumulation in cells, tissues, and organs. The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutated gene for a child to be affected.

Risk Factors

• Family history of MPS I or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for IDUA mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, and hearing loss.
• Respiratory and cardiac complications due to tissue thickening.

Diagnosis

Diagnosis involves measuring alpha-L-iduronidase enzyme activity in blood or tissue samples, which is typically reduced in affected individuals. Confirmatory testing may include genetic analysis of the IDUA gene. Newborn screening for MPS I is available in some regions, and imaging studies (e.g., X-rays, MRI) may assess skeletal or organ involvement.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Enzyme replacement therapy (ERT) with laronidase is used to reduce GAG accumulation. Hematopoietic stem cell transplantation (HSCT) may be considered for severe cases, particularly to address neurological symptoms. Supportive care includes physical therapy, surgery for skeletal or organ complications, and regular monitoring of organ function.

Prognosis and Follow-Up

Prognosis varies by disease subtype (Hurler, Hurler-Scheie, or Scheie) and the severity of symptoms. Early intervention, especially with ERT or HSCT, can improve outcomes and extend life expectancy. Regular follow-up with a multidisciplinary team (e.g., geneticists, neurologists, orthopedic specialists) is essential to monitor organ function, manage complications, and adjust treatment plans.

Complications

• Progressive neurological decline, including cognitive impairment.
• Respiratory insufficiency due to airway obstruction or restrictive lung disease.
• Cardiac complications, such as valvular heart disease or cardiomyopathy.
• Vision or hearing loss from corneal clouding or nerve damage.
• Skeletal deformities requiring surgical intervention.

Lifestyle & Prevention

• Genetic counseling for families with a history of MPS I to assess recurrence risk.
• Prenatal testing (e.g., chorionic villus sampling or amniocentesis) for at-risk pregnancies.
• Regular monitoring of organ function and early intervention to prevent complications.
• Supportive therapies (e.g., physical therapy, occupational therapy) to maintain mobility and quality of life.

When to Seek Professional Help

Seek immediate medical attention if symptoms worsen rapidly, especially respiratory distress, severe pain, or sudden neurological changes. Regular follow-up with a specialist is recommended for ongoing management of organ function and treatment efficacy.

Tips for Medical Coders

When coding for MPS I (E76.0), ensure documentation supports the diagnosis, including enzyme activity levels, genetic testing results, or clinical findings consistent with the condition. Differentiate between subtypes (e.g., Hurler syndrome) if specified, as this may impact coding and treatment documentation. Verify that all associated complications (e.g., organ enlargement, skeletal abnormalities) are appropriately coded to reflect the full clinical picture.